XENON PHARMACEUTICALS INC. — Income Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$0
R&D↑+47.5% +$28M
$88M
D&A↓-3.5% -$22K
$611K
Operating Income↓-30.8% -$23M
$-96M
EBITDA↓-3.5% -$22K
$611K
Interest Expense
—
Interest Income↓-43.3% -$4M
$5M
Other Income/Expense↓-137.6% -$326K
$-89K
Pretax Income↓-43.0% -$27M
$-90M
Tax Provision
$339K
Net Income↓-44.8% -$28M
$-91M
Operating Margin
-969.8%
Net Margin
-867.3%
Effective Tax Rate↓-1.3pts
-0.8%
Deferred Tax Assets↓-87.1% -$7M
$1M
ETR (Continuing Operations)↓-2.0pts
-0.3%
ETR Federal Statutory↓-12.0pts
15.0%
Operating Lease Cost↓-0.5% -$2K
$410K
Revenue YoY Variation
—
Income YoY Variation↑+1.6pts
-30.8%
Revenue QoQ Variation
-100.0%
Income QoQ Variation↑+4.4pts
-2.2%